Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges

Reza Pratama, Muhaimin Muhaimin, Miski Khairinisa, Anis Chaerunisaa

Open source

DOI
10.2147/tcrm.s601774
Published
2026-05
Container
Therapeutics and Clinical Risk Management
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/tcrm.s601774,
  title = {Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges},
  author = {Reza Pratama and Muhaimin Muhaimin and Miski Khairinisa and Anis Chaerunisaa},
  year = {2026},
  journal = {Therapeutics and Clinical Risk Management},
  doi = {10.2147/tcrm.s601774},
  url = {https://doi.org/10.2147/tcrm.s601774}
}

RIS

TY  - JOUR
TI  - Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges
AU  - Reza Pratama
AU  - Muhaimin Muhaimin
AU  - Miski Khairinisa
AU  - Anis Chaerunisaa
PY  - 2026
JO  - Therapeutics and Clinical Risk Management
DO  - 10.2147/tcrm.s601774
UR  - https://doi.org/10.2147/tcrm.s601774
ER  - 

APA

Pratama, R., Muhaimin, M., Khairinisa, M., & Chaerunisaa, A. (2026). Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. Therapeutics and Clinical Risk Management. https://doi.org/10.2147/tcrm.s601774

Source records